Finanzen von Whitehawk Therapeutics Inc (WHWK)WHWKWhitehawk Therapeutics Inc

Evaluating the bottom line, Whitehawk Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -44.98%, provide a clear picture of how effectively WHWK converts its operational activities into shareholder value.

In the context of the broader market, WHWK competes directly with industry leaders such as RNA and ZNTL. With a market capitalization of $174.45M, it holds a leading position in the sector. When comparing efficiency, WHWK's gross margin of N/A stands against RNA's 100.00% and ZNTL's N/A. Such benchmarking helps identify whether Whitehawk Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 89.09% in Q4 2024, indicating strong profitability potential despite recent losses. However, net income has been negative, with a reported loss of $22,194,000 in Q1 2026.